Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010

Fig. 1

A. RFS curves according to pathological stage. The 5-year RFS rates was 88.5% in patients with stage IA, 72.0% in stage IB, 49.2% in stage IIA, 43.0% in stage IIB and 27.5% in stage IIIA. B. RFS curves according to histologic predominance. The 5-year RFS rates was 94.5% in patients with AIS, 91.7% in MIA, 84.5% in lepidic, 73.6% in variants, 69.0% in papillary, 65.3% in acinar, 51.6% in micropapillary, and 51.4% in solid. C RFS curves for each histological groups in pathological stage I. The 5-year RFS rate was 92.2% in patients with group A (AIS + MIA), 89.3% in group B (lepidic), 79.2% in group C (papillary + acinar + variants) and 69.0% in group D (solid + micropapillary). D RFS curves of each histological groups in pathological stage II + IIIA. The 5-year RFS rates was 43.6% in patients with group B, 39.5% in group C and 31.0% in group D

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us